A Phase 2 interventional study of Sinemet and IPX203 in Advanced Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 11 sites in United States. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-06-06.
Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 2, and was the 11th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:
Impax Laboratories, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 40 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2016.
This study's enrollment of 28 is below the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 77 across the 14 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Impax Laboratories, LLC, one of the names counted as Amneal Pharmaceuticals, Inc.. Under that name alone:
Impax Laboratories, LLC is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To compare the pharmacokinetics (PK) of single and multiple doses of IPX203 with Immediate release carbidopa-levodopa (IR CD-LD) in subjects with advanced Parkinson's disease (PD).
Secondary Objectives:
To compare the pharmacodynamics of single and multiple doses of IPX203 with IR CD-LD.
To compare the efficacy of IPX203 with IR CD-LD following multiple doses.
To evaluate the safety of IPX203.
IPX203 is an investigational product containing CD-LD.
IPX203-B16-01 Study Design:
A randomized, open-label, rater-blinded, multicenter, 2-treatment, 2-period, multiple-dose crossover study.
Approximately 30 qualified IR CD-LD-experienced advanced PD subjects will be randomized.
The study duration will be approximately 8 weeks, including the screening period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligibility will be determined at screening and Visit 1 of the study.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants first received IPX203 ER CD-LD Capsules for 15 days After a Washout Period of 7 days; participants then received Sinemet (IR CD-LD) Tablet for 15 days Study drug doses were determined based on the subject's prestudy IR CD-LD regimen The typical IPX203 dosing regimen was 3 times a day, dosed approximately every 7 to 8 hours.
Drug: Sinemet · Drug: IPX203
Participants first received Sinemet Capsules for 15 days After a Washout Period of 7 days; participants then received IPX203 ER CD-LD Capsules for 15 days Study drug doses were determined based on the subject's prestudy IR CD-LD regimen The typical IPX203 dosing regimen was 3 times a day, dosed approximately every 7 to 8 hours.
Drug: Sinemet · Drug: IPX203
Immediate Release Tablet containing carbidopa-levodopa flexible dosing
Also known as: IR CD-LD Tablets
Extended Release capsules containing carbidopa-levodopa flexible dosing
Also known as: IPX203 ER CD-LD Capsules
Levodopa Cmax Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Levodopa Tmax Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Levodopa t1/2 Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Levodopa AUCt Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Levodopa AUCinf Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Levodopa Bioavailability Relative to IR CD/LD Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Carbidopa Cmax Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Carbidopa Tmax Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Carbidopa t1/2 Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Carbidopa AUCt Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Carbidopa AUCinf Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Carbidopa Bioavailability Relative to IR CD/LD Following First Dose on Day 1
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
Time frame: Day 1
Levodopa Cmax Following First Dose on Day 15
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
Time frame: Day 15
Levodopa Tmax Following First Dose on Day 15
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
Time frame: Day 15
Levodopa AUCtau Following First Dose on Day 15
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
Time frame: Day 15
Carbidopa Cmax Following First Dose on Day 15
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
Time frame: Day 15
Carbidopa Tmax Following First Dose on Day 15
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
Time frame: Day 15
Carbidopa AUCtau Following First Dose on Day 15
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
Time frame: Day 15
A total of 39 subjects were screened at 10 study sites between November 8, 2016 and August 1, 2017
| Milestone | IPX203 First Then Sinemet | Sinemet First Then IPX203 |
|---|---|---|
| Started | 15 | 13 |
| Completed | 14 | 13 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | IPX203 First Then Sinemet | Sinemet First Then IPX203 |
|---|---|---|
| Started | 14 | 13 |
| Completed | 14 | 13 |
| Not completed | 0 | 0 |
| Milestone | IPX203 First Then Sinemet | Sinemet First Then IPX203 |
|---|---|---|
| Started | 14 | 13 |
| Completed | 14 | 13 |
| Not completed | 0 | 0 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| ng/mL | IPX203 | Sinemet |
|---|---|---|
| Levodopa Cmax Following First Dose on Day 1 | 2857.56 ± 1204.506 | 2173.30 ± 1240.774 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| hour | IPX203 | Sinemet |
|---|---|---|
| Levodopa Tmax Following First Dose on Day 1 | 2.07 ± 0.997 | 0.94 ± 0.560 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| hour | IPX203 | Sinemet |
|---|---|---|
| Levodopa t1/2 Following First Dose on Day 1 | 1.658 ± 0.4838 | 1.420 ± 0.3194 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| ng.h/mL | IPX203 | Sinemet |
|---|---|---|
| Levodopa AUCt Following First Dose on Day 1 | 12107.60 ± 5793.881 | 3747.61 ± 1819.141 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| ng.h/mL | IPX203 | Sinemet |
|---|---|---|
| Levodopa AUCinf Following First Dose on Day 1 | 13968.57 ± 7606.901 | 4308.37 ± 2123.057 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| Percentage | IPX203 | Sinemet |
|---|---|---|
| Levodopa Bioavailability Relative to IR CD/LD Following First Dose on Day 1 | 88.965 ± 21.7583 | 0 ± 0 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| ng/mL | IPX203 | Sinemet |
|---|---|---|
| Carbidopa Cmax Following First Dose on Day 1 | 500.35 ± 316.299 | 151.50 ± 103.225 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| hour | IPX203 | Sinemet |
|---|---|---|
| Carbidopa Tmax Following First Dose on Day 1 | 2.61 ± 0.655 | 2.07 ± 0.675 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| hour | IPX203 | Sinemet |
|---|---|---|
| Carbidopa t1/2 Following First Dose on Day 1 | 2.015 ± 0.5159 | 1.969 ± 0.7187 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| ng.h/mL | IPX203 | Sinemet |
|---|---|---|
| Carbidopa AUCt Following First Dose on Day 1 | 1940.51 ± 1095.449 | 436.63 ± 286.286 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| ng.h/mL | IPX203 | Sinemet |
|---|---|---|
| Carbidopa AUCinf Following First Dose on Day 1 | 2239.61 ± 1232.234 | 610.44 ± 407.305 |
Single Dose predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours postdose
| Percentage | IPX203 | Sinemet |
|---|---|---|
| Carbidopa Bioavailability Relative to IR CD/LD Following First Dose on Day 1 | 117.442 ± 43.4176 | 0 ± 0 |
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
| ng/mL | IPX203 | Sinemet |
|---|---|---|
| Levodopa Cmax Following First Dose on Day 15 | 2767.96 ± 1258.525 | 2356.85 ± 1178.628 |
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
| hour | IPX203 | Sinemet |
|---|---|---|
| Levodopa Tmax Following First Dose on Day 15 | 1.91 ± 1.241 | 0.83 ± 0.439 |
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
| ng.h/ML | IPX203 | Sinemet |
|---|---|---|
| Levodopa AUCtau Following First Dose on Day 15 | 11213.76 ± 4887.246 | 3879.39 ± 1744.328 |
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
| ng/mL | IPX203 | Sinemet |
|---|---|---|
| Carbidopa Cmax Following First Dose on Day 15 | 478.66 ± 290.584 | 145.67 ± 82.541 |
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
| hour | IPX203 | Sinemet |
|---|---|---|
| Carbidopa Tmax Following First Dose on Day 15 | 2.52 ± 0.74 | 2.20 ± 0.639 |
Multiple Dose predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, and 10 hours postdose.
| ng.h/mL | IPX203 | Sinemet |
|---|---|---|
| Carbidopa AUCtau Following First Dose on Day 15 | 1892.39 ± 1017.537 | 415.83 ± 279.487 |
Collected over 15 days for each intervention plus 1 week washout up to a total of 37 days. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IPX203 | 0/28 (0%) | 1/28 (3.6%) | 10/28 (35.7%) |
| Sinemet | 0/27 (0%) | 0/27 (0%) | 2/27 (7.4%) |
| Washout Period | 0/28 (0%) | 1/28 (3.6%) | 0/28 (0%) |
| Event | IPX203 | Sinemet | Washout Period |
|---|---|---|---|
| HypertensionVascular disorders | 1/28 | 0/27 | 0/28 |
| DiarrhoreaGastrointestinal disorders | 0/28 | 0/27 | 1/28 |
| DehydrationMetabolism and nutrition disorders | 0/28 | 0/27 | 1/28 |
| Atrial FibrillationCardiac disorders | 0/28 | 0/27 | 1/28 |
| Event | IPX203 | Sinemet | Washout Period |
|---|---|---|---|
| DyskinesiaNervous system disorders | 5/28 | 0/27 | 0/28 |
| NauseaGastrointestinal disorders | 2/28 | 0/27 | 0/28 |
| DizzinessNervous system disorders | 2/28 | 0/27 | 0/28 |
| Abdominal PainGastrointestinal disorders | 0/28 | 1/27 | 0/28 |
| DiarrhoeaGastrointestinal disorders | 0/28 | 1/27 | 0/28 |
| Upper respiratiory track infectionInfections and infestations | 0/28 | 1/27 | 0/28 |
| Dry MouthGastrointestinal disorders | 1/28 | 0/27 | 0/28 |
| VomitingGastrointestinal disorders | 1/28 | 0/27 | 0/28 |
| BronchitisInfections and infestations | 1/28 | 0/27 | 0/28 |
| Urinary Tract infectionInfections and infestations | 1/28 | 0/27 | 0/28 |
Subjects who were enrolled and randomized to 1 of 2 treatment sequences
| Age, Categorical(Participants) | All Study Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 13 |
| >=65 years | 15 |
| Age, Continuous(Years) | All Study Participants |
|---|---|
| Mean | 66.43 ± 10.057 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Gender — Female | 12 |
| Gender — Male | 16 |
| Ethnicity (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 27 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 26 |
| More than one race | 2 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | All Study Participants |
|---|---|
| United States | 28 |
| Age at Parkinson's disease onset(years) | All Study Participants |
|---|---|
| Mean | 58.9 ± 11.8 |
| Duration of Parkinson's disease(years) | All Study Participants |
|---|---|
| Mean | 7.5 ± 4.8 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in Aug 2017, 8 months.
Results were first posted in Jun 2022, 4 years 10 months after primary completion. A results delay was requested in Aug 2018.
Of 96 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 8 months is below that.
Counting every sponsor, half of 201 studies reached it within 28 months; a quarter within 16 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IPX203